References ↵ Lopez Pineiro M, Willis E, Yao C, et al . Pyoderma gangrenosum-like ulceration of the lower extremity secondary to sunitinib therapy: a case report. SAGE Open Med Case Rep 2018; 6: ...

Send comments and news tips to [email protected]. Cite this: Edited by Deepa Varma. Pyoderma Gangrenosum in Pregnancy Often Misdiagnosed - Medscape - July 11, 2025.

Orphan Drug Designation granted for treatment of pyoderma gangrenosum (PG) from US FDA and EMAProductive end-of-phase II meeting with FDA held for PG; dialogue ongoing related to Phase III program ...

JENA, Germany, March 08, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement ...

Erosive pustular dermatosis has a striking clinical presentation and may be mistaken for cutaneous malignancy. Clinicopathologic correlation is critical because histopathology is nonspecific; thus, ...

InflaRx has taken the difficult decision to abandon its drug development programme, vilobelimab, for rare inflammatory skin disorder pyoderma gangrenosum (PG), a move that has pummelled its share ...

Phase 3 pyoderma gangrenosum trial was halted after analysis of 30 patients showed no efficacy signal. InflaRx to prioritize INF904 with key data expected in chronic spontaneous urticaria and ...

After a poor showing of its COVID med vilobelimab in a rare skin disorder trial, German drugmaker InflaRx is going back to the drawing board.